Robert R. Redfield former CDC Director

Key note Speech 1) With COVID-19, how will our daily lives change? & How will treatments and vaccines be applied?

-Former CDC Director
-Former professor at University of Maryland School of Medicine
-President's Advisory Council on HIV/AIDS
-Discharged as Colonel, U.S. Army Medical Corps.
-Residency at Walter Reed Army Medical Center
-Medical Doctor from Georgetown University School of Medicine

Ki Suk, Jung Professor of Pulmonary at Hallym University Sacred Heart Hospital

1:1 discussion)

-Professor of Pulmonary at Hallym University Sacred Heart Hospital
-President of the 2022 Asia-Pacific Respiratory Society Seoul Conference
-Former commissioner of Korea Disease Control and Prevention Agency
-Intern/Fellow at Seoul National University Hospital
-MD, Pd.D in internal medicine, Seoul National University Medical School

Hyunsang Muk CEO, Korea Drug Development Fund

Key note Speech 2) Task of 'K-Bio' in the era of with COVID-19

-CEO, Korea Drug Development Fund
-Head of the business division, Korea Drug Development Fund
-Member of the Investment Deliberation Committee, Korea Drug Development Fund
-Director, Korea Bio(Korea Biotechnology Industry Organization)
-CEO, Medifron
-BS, MS in Industrial Engineering, Seoul National University

Hyungwook Lim Sr. Principal Scientist, Cell Therapy Lab at Novartis Institutes for BioMedical (NIBR)

Session) Reimagining new ground in cancer treatment : Present and future of CAR-T

-Sr. Principal Scientist, Cell Therapy Lab at Novartis Institutes for BioMedical (NIBR)
-Area of Expertise: Immuno-Oncology, Chimeric Antigen Receptor T cells (CART), Cell Therapy, and T cell biology
-Scientist at Gladstone Institutes (UCSF)
-Ph.D. in Immunology, Purdue University
- M.S. in Biochemistry, Seoul National University
- B.S. in Chemistry, Seoul National University

Bill Enright CEO, Vaccitech

Session) COVID-19 vaccine platform and the development of new anticancer drugs

-CEO, Vaccitech
-Director, President & CEO, Altimmune
-Head of Business Development, GenVec
-More than thirty years of experience in building and financing both privately held and publicly held companies
-MS in Business Management, Johns Hopkins University.
-MA in Molecular Biology, State University　of NewYork

Donghoon Lee Executive Vice President, SK Holdings(Bio investment Center)

Session) K-Bio. Requirements for taking the lead, 'M&A'

-Executive Vice President, SK Holdings(Bio investment Center)
-Vice president, global business, Dong-A ST
-Vice president, Dong-A Socio Holdings
-Executive Director, Investment Advisory, KPMG
-KPMG New York
-MBA, Ohio State University
-BA in Business management, Seoul National University

Jisoo Pae CEO, Genome & Company

Session) M&A, K-Bio Venture's growth catalyst

-CEO, Genome & Company
-Director, External Cooperation at MSD Korea
-Consultant at Bain&Company
-MBA, Duke University
-Seoul National University Medical School

James Choi Director, Global Information Marketing Center at SamsungBiologics

Session) Attention from the world, Samsung Biologics' global CDMO strategy

-Director, Global Information Marketing Center at SamsungBiologics
-Team leader at GlO Team, SamsungBiologics
-MBA, University of Southern California
-BS in Mechenichal Engineering, University of California at Irvine